bevenopran (CB-5945) / Eli Lilly, Merck (MSD) - LARVOL DELTA

New developments in the treatment of opioid-induced gastrointestinal symptoms. (PubMed, United European Gastroenterol J) - "This review summarises current and emerging treatment options for OIC based on an extensive bibliographical search. Efficacy data for laxatives, lubiprostone, prucalopride, linaclotide, oxycodone/naloxone combinations, methylnaltrexone, alvimopan, naloxegol, naldemedine, axelopran, and bevenopran in OIC are summarised."

Journal • Review • Biosimilar • Pain

Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation (clinicaltrials.gov) - P3; N=61; Terminated; Sponsor: Cubist Pharmaceuticals; Trial primary completion date: Mar 2015 ->Jan 2014

Trial primary completion date • Biosimilar • Pain

Single Oral Dose of Bevenopran in Patients With Varying Degrees of Renal Impairment (clinicaltrials.gov) - P1; N=31; Terminated; Sponsor: Cubist Pharmaceuticals Holdings LLC

New P1 trial • Biosimilar • Renal Disease